Stock CSTL CASTLE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX
Other stock markets
 12:41:07 2024-04-30 EDT 		5-day change 1st Jan Change
21.06 USD -2.18% Intraday chart for Castle Biosciences, Inc. +5.63% -1.81%
04-08 Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing MT
04-04 Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress CI

Business Summary

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Number of employees: 610

Sales per Business

USD in Million2022Weight2023Weight Delta
Dermatologic
83.4 %
125 91.1 % 183 83.4 % +46.92%
Non-Dermatologic
16.6 %
12 8.9 % 36 16.6 % +197.74%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
137 100.0 % 220 100.0 % +60.38%

Managers

Managers TitleAgeSince
Derek Maetzold FOU
 Founder 62 07-08-31
Franklin Stokes DFI
 Director of Finance/CFO 54 17-11-30
Johnson Clare CTO
 Chief Tech/Sci/R&D Officer - 21-06-30
Chris Otte CTO
 Chief Tech/Sci/R&D Officer - -
Matthew Goldberg CTO
 Chief Tech/Sci/R&D Officer - 20-07-31
Robert W. Cook CTO
 Chief Tech/Sci/R&D Officer 52 11-01-31
Kristen Oelschlager COO
 Chief Operating Officer 56 08-09-30
Camilla Zuckero IRC
 Investor Relations Contact - 19-09-30
Kevin Doman SAM
 Sales & Marketing - 22-05-31
Keli Greenberg HRO
 Human Resources Officer - 20-06-30

Members of the board

Members of the board TitleAgeSince
Derek Maetzold FOU
 Founder 62 07-08-31
Daniel Bradbury CHM
 Chairman 62 12-08-31
G. Cole BRD
 Director/Board Member 68 18-12-05
Tiffany Olson BRD
 Director/Board Member 64 21-05-07
Mara Aspinall BRD
 Director/Board Member 61 15-02-23
Kimberlee Caple BRD
 Director/Board Member 62 21-07-15
Ellen Goldberg BRD
 Director/Board Member 50 21-07-15
Miles Harrison BRD
 Director/Board Member 59 20-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,587,062 26,749,980 ( 96.97 %) 0 96.97 %

Shareholders

NameEquities%Valuation
Wasatch Advisors, Inc.
9.294 %
2,551,088 9.294 % 57 M $
Granahan Investment Management, LLC
7.892 %
2,166,471 7.892 % 48 M $
BlackRock Advisors LLC
7.607 %
2,088,218 7.607 % 46 M $
Principal Global Investors LLC
5.777 %
1,585,673 5.777 % 35 M $
Vanguard Fiduciary Trust Co.
5.324 %
1,461,481 5.324 % 32 M $
Bellevue Asset Management AG
4.490 %
1,232,378 4.490 % 27 M $
Deerfield Management Co. LP (Private Equity)
3.517 %
965,428 3.517 % 21 M $
Portolan Capital Management LLC
2.654 %
728,653 2.654 % 16 M $
Millennium Management LLC
2.610 %
716,350 2.610 % 16 M $
Dimensional Fund Advisors LP
2.419 %
663,882 2.419 % 15 M $

Company contact information

Castle Biosciences, Inc.

505 South Friendswood Drive Suite 401

77546, Friendswood

+

http://www.castlebiosciences.com
address Castle Biosciences, Inc.(CSTL)

Sector

Healthcare
Healthcare Services
Healthcare Equipment & Supplies
Medical Equipment, Supplies & Distribution
Diagnostic & Testing Substances

Sales per Business

Ratings for Castle Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
21.53 USD
Average target price
33.11 USD
Spread / Average Target
+53.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
CASTLE BIOSCIENCES, INC. Stock Castle Biosciences, Inc.
-1.81% 594M
BIOMÉRIEUX Stock bioMérieux
-0.60% 12.95B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-9.59% 7.84B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.82% 5.5B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.61B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+7.44% 4.61B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-47.62% 3.4B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.42% 2.66B
VITROLIFE AB Stock Vitrolife AB
-14.59% 2.08B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+2.25% 1.79B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. CSTL Stock
  4. Company Castle Biosciences, Inc.